Free Trial
NASDAQ:BMEA

Biomea Fusion Q2 2026 Earnings Results & Report

Biomea Fusion logo
$0.60 +0.05 (+9.69%)
As of 10:58 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Biomea Fusion beat analyst earnings expectations in its Q2 2026 results, released August 5, 2026. The company reported EPS of -$0.12 versus the -$0.2235 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Biomea Fusion EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.2235
Beat/Miss
Beat by +$0.1035
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Biomea Fusion Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biomea Fusion Q2 2026 Earnings FAQ

Biomea Fusion (NASDAQ:BMEA) reported earnings of -$0.12 per share for Q2 2026, beating the consensus estimate of -$0.2235. The report was announced on Wednesday, August 5, 2026.

Biomea Fusion Earnings Headlines

My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
Biomea Fusion (BMEA) Projected to Post Quarterly Earnings on Tuesday
See More Biomea Fusion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biomea Fusion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomea Fusion and other key companies, straight to your email.

About Biomea Fusion

Biomea Fusion (NASDAQ:BMEA) is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for cancer and metabolic diseases. The company uses its proprietary FUSION System to discover and develop covalent medicines designed to engage disease-relevant protein targets.

Biomea’s lead investigational product is BMF-219, an oral, selective covalent inhibitor of menin. The company has evaluated BMF-219 in clinical studies for certain hematologic malignancies and solid tumors, including acute leukemias and multiple myeloma, and has also investigated its potential in metabolic diseases such as type 2 diabetes. BMF-500 is another investigational program intended to target menin-related biology.

Founded in 2017 and headquartered in Redwood City, California, Biomea Fusion conducts research and clinical development activities aimed at addressing diseases with significant unmet medical needs. The company is led by Thomas Butler, who serves as co-founder, chairman and chief executive officer. Its programs are investigational and have not been approved for commercial use by regulatory authorities.

View Biomea Fusion Profile